The endogenous p95 ErbB2 in BT474 breast cancer cells does not respond to EGF as the full-length ErbB2, but instead gets phosphorylated and activated in response to ErbB3 and ErbB4 ligand heregulin [49]. This evidence concerns the gene ERBB3 and breast cancer.